Met Non Small Cell Cancer Registry (MOMENT)

Recruiting

• Conditions: Cancer

• Registration Number: NCT05376891
• Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Brief Summary

The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time.

The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.

Detailed Description

This is a disease registry, which is an organized system using non-interventional methods to collect data on a patient population defined by a particular disease, exposure, or condition, and which is followed over time. Non-interventional means that after participants enrollment, participants will be treated according to the routine clinical treatment decision by the physician. The registry will not impose any treatment or procedure for participants.

Study Timeline

• Study First Submitted: 2022-05-11
• Study First Submitted QC: 2022-05-11
• Study First Posted: 2022-05-17
• Study Start: 2022-10-04
• Status Verified: 2025-06
• Last Update Submitted: 2025-06-18
• Last Update Posted: 2025-06-19
• Primary Completion: 2027-03-31
• Study Completion: 2027-03-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 700

Inclusion Criteria

• Participants who signed ICF
• Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
• Participants who are starting or are already being treated with systemic therapy

Exclusion Criteria

• Participants who are enrolled in a clinical trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Best Overall Response (BOR)	Through study completion, up to approximately 4.9 years
Overall Survival (OS)	Through study completion, up to approximately 4.9 years
Tumor Response According to Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1	Up to approximately 4.9 years
Number of Participants with Adverse Events (AEs)	Up to approximately 4.9 years
Number of Participants with Adverse Reactions (ARs)	Up to approximately 4.9 years

Trial Locations

Locations (64)

Holy Cross Health; 🇺🇸 Fort Lauderdale, Florida, United States

The Ohio State University Wexner Medical Center; 🇺🇸 Columbus, Ohio, United States

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States

Klinikum Klagenfurt Am Woerthersee; 🇦🇹 Klagenfurt am Wörthersee, Austria

Klinik Floridsdorf; 🇦🇹 Wien, Austria

AZ Delta; 🇧🇪 Roeselare, Belgium

AZ Nikolaas; 🇧🇪 Sint-Niklaas, Belgium

Ottawa Hospital General Campus; 🇨🇦 Ottawa, Canada

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Canada

FN Olomouc; 🇨🇿 Olomouc, Czechia

Scroll for more (54 remaining)